9 results on '"Zan Shen"'
Search Results
2. The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data.
- Author
-
Hongtao Li, Daliu Min, Hui Zhao, Zhiyu Wang, Weixiang Qi, Shuier Zheng, Lina Tang, Aina He, Yuanjue Sun, Yang Yao, and Zan Shen
- Subjects
Medicine ,Science - Abstract
The significance of ezrin immunoexpression and prognosis for osteosarcoma is still controversial. The aim was to provide a meta-analysis for ezrin immunoexpression and prognostic features of osteosarcoma patients.A detailed search was made in MEDLINE, EMBASE and the Web of Knowledge for relevant original articles published in English; methodological quality of the included studies was also assessed. Two reviewers extracted data independently. Studies were pooled and summary hazard ratios (HRs) and odds ratio (ORs) with corresponding confidence intervals (CIs) were calculated.Final analysis of 318 patients from 5 eligible studies was performed. Combined HR of ezrin immunohistochemical staining suggested that positive immunoexpression had an unfavorable impact on osteosarcoma patients' overall survival (n = 223 in 4 studies; HR = 4.79; 95% CI: 1.50-15.30; P = 0.008) but not on event-free survival (n = 202 in 3 studies; HR = 1.59; 95% CI: 0.61-4.15; P = 0. 0.342). Combined OR of ezrin immunohistochemical staining indicated that positive immunoexpression was associated with recurrence (n = 134 in 2 studies; OR = 3.79; 95% CI: 1.49-9.64; P = 0.005) but not with serum ALP level (n = 160 in 2 studies; OR = 2.16; 95% CI: 0.09-52.50; P = 0.637) and histological response to neoadjuvant chemotherapy(n = 260 in 4 studies; OR = 0.87; 95% CI: 0.37-2.03; P = 0.740).The results of this meta-analysis suggest that ezrin positive immunoexpression confers a higher risk of recurrence and a worse survival in osteosarcoma patients. Large prospective studies are needed to provide solid data to investigate the precise prognostic significance of ezrin.
- Published
- 2013
- Full Text
- View/download PDF
3. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
- Author
-
Wei-Xiang Qi, Yu-Jing Huang, Yang Yao, Zan Shen, and Da-Liu Min
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Two novel mammalian targets of rapamycin (mTOR) inhibitors everolimus and temsirolimus are now approved by regulatory agencies and have been widely investigated among various types of solid tumors, but the risk of fatal adverse events (FAEs) with these drugs is not well defined. METHODS: We searched PubMed, EMBASE, and Cochrane library databases for relevant trials. Eligible studies included prospective phase II and III trials evaluating everolimus and temsirolimus in patients with all malignancies and data on FAEs were available. Statistical analyses were conducted to calculate the summary incidence, RRs and 95% confidence intervals (CIs) by using either random effects or fixed effect models according to the heterogeneity of the included studies. RESULTS: A total of 3322 patients with various advanced solid tumors from 12 trials were included. The overall incidence of mTOR inhibitors associated FAEs was 1.8% (95%CI: 1.3-2.5%), and the incidences of everolimus related FAEs were comparable to that of temsirolimus (1.7% versus 1.8%). Compared with the controls, the use of mTOR inhibitors was associated with an increased risk of FAEs, with a RR of 3.24 (95%CI: 1.21-8.67, p = 0.019). On subgroup analysis, a non-statistically significant increase in the risk of FAEs was found according to different mTOR inhibitors, tumor types or controlled therapy. No evidence of publication bias was observed. CONCLUSION: With the present evidence, the use of mTOR inhibitors seems to increase the risk of FAEs in patients with advanced solid tumors. More high quality trials are still needed to investigate this association.
- Published
- 2013
- Full Text
- View/download PDF
4. Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.
- Author
-
Kun Han, WeiXiang Qi, ZhiHua Gan, Zan Shen, Yang Yao, and DaLiu Min
- Subjects
Medicine ,Science - Abstract
PURPOSE: Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial. METHODS: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. RESULTS: Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60-2.39; P
- Published
- 2013
- Full Text
- View/download PDF
5. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.
- Author
-
Wei-Xiang Qi, Qiong Wang, Yan-Ling Jiang, Yuan-Jue Sun, Li-Na Tang, Ai-Na He, Da-Liu Min, Feng Lin, Zan Shen, and Yang Yao
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. METHODS: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3 or 4 adverse event (AEs). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. RESULTS: Eight eligible trials involved 2417 patients were ultimately identified. The intention to treatment (ITT) analysis demonstrated that combining targeted therapy significantly improved OS (HR 0.90, 95% CI: 0.82-0.99, p = 0.024), PFS (HR 0.83, 95% CI: 0.72-0.97, p = 0.018), and ORR (OR 1.35, 95% CI 1.01-1.80, P = 0.04). Sub-group analysis based on phases of trials, EGFR-status and KRAS status also showed that there was a tendency to improve PFS and OS in combining targeted therapy, except that PFS for patients with EGFR-mutation or wild type KRAS favored erlotinib monotherapy. Additionally, more incidence of grade 3 or 4 rash, fatigue and hypertension were observed in combining targeted therapy. CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. More studies are still needed to identify patients who will most likely benefit from the appropriate combining targeted therapy.
- Published
- 2013
- Full Text
- View/download PDF
6. Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis
- Author
-
Zan Shen, Na Zhang, Yang Yao, Aina He, Yonggang Wang, Yuanjue Sun, Hongtao Li, Zimei Liu, Wentao Huang, and Yuan Yuan
- Subjects
Male ,0301 basic medicine ,Pathology ,Physiology ,medicine.medical_treatment ,Cancer Treatment ,lcsh:Medicine ,Disease ,Gastroenterology ,Metastasis ,0302 clinical medicine ,Animal Cells ,Basic Cancer Research ,Medicine and Health Sciences ,Platelet ,Femur ,Stage (cooking) ,lcsh:Science ,Musculoskeletal System ,Osteosarcoma ,Multidisciplinary ,Pharmaceutics ,Sarcomas ,Platelet Distribution Width ,Hematology ,Body Fluids ,Blood ,Oncology ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,Anatomy ,Cellular Types ,Mean Platelet Volume ,Research Article ,Platelets ,Clinical Oncology ,Adult ,medicine.medical_specialty ,Adolescent ,Bone Neoplasms ,Disease-Free Survival ,Cancer Chemotherapy ,Young Adult ,03 medical and health sciences ,Drug Therapy ,Internal medicine ,medicine ,Chemotherapy ,Humans ,Mean platelet volume ,Blood Coagulation ,Skeleton ,Blood Cells ,Platelet indices ,Platelet Count ,business.industry ,lcsh:R ,Biology and Life Sciences ,Cancers and Neoplasms ,Cell Biology ,Platelet Activation ,medicine.disease ,030104 developmental biology ,Metastatic Tumors ,Fibula ,lcsh:Q ,Clinical Medicine ,business - Abstract
Purpose The purpose of this study was to investigate the relationship between platelet indices [mean platelet volume (MPV), platelet count (PLT), platelet distribution width (PDW) and plateletcrit (PCT)] at diagnosis in osteosarcoma. Methods The information of 233 patients with osteosarcoma at diagnosis between 2007 and 2015 was retrospectively reviewed. Clinical parameters such as gender, age, size and site of tumor, and tumor necrosis rate after neoadjuvant chemotherapy were analyzed. Results No significant difference was noted in the mean values of MPV, PLT, PDW and PCT among stage I, II and III patients. In localized patients, the median disease-free survival (DFS) values were 42 and 22 months in the PLT
- Published
- 2017
7. Prognostic Value of Ezrin in Solid Tumors: A Meta-Analysis of the Literature
- Author
-
Wei-Xiang Qi, Daliu Min, Yang Yao, Zhihua Gan, Zan Shen, and Kun Han
- Subjects
Oncology ,medicine.medical_specialty ,Clinical Research Design ,Cancer Treatment ,lcsh:Medicine ,Gene Expression ,Subgroup analysis ,Bioinformatics ,Biochemistry ,Ezrin ,Internal medicine ,Neoplasms ,Molecular Cell Biology ,Basic Cancer Research ,medicine ,Humans ,lcsh:Science ,Biology ,Proportional Hazards Models ,Multidisciplinary ,business.industry ,Proportional hazards model ,Cancer Risk Factors ,Hazard ratio ,lcsh:R ,Proteins ,Cancers and Neoplasms ,Publication bias ,Odds ratio ,Chemotherapy and Drug Treatment ,Prognosis ,Confidence interval ,Cytoskeletal Proteins ,Meta-analysis ,Medicine ,lcsh:Q ,Meta-Analyses ,business ,Publication Bias ,Research Article - Abstract
Purpose Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial. Methods Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. Results Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60–2.39; P
- Published
- 2013
8. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data
- Author
-
Zan Shen, Wei-Xiang Qi, Yuanjue Sun, Feng Lin, Qiong Wang, Daliu Min, Yang Yao, Yan-Ling Jiang, Li-Na Tang, and Aina He
- Subjects
Oncology ,medicine.medical_specialty ,Drugs and Devices ,Lung Neoplasms ,medicine.medical_treatment ,Cancer Treatment ,lcsh:Medicine ,Pharmacology ,Lung and Intrathoracic Tumors ,law.invention ,Targeted therapy ,Databases ,Randomized controlled trial ,law ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Molecular Cell Biology ,Tyrosine Kinase Signaling Cascade ,medicine ,Carcinoma ,Humans ,Lung cancer ,lcsh:Science ,neoplasms ,Biology ,Survival analysis ,Chemotherapy ,Multidisciplinary ,business.industry ,lcsh:R ,Cancers and Neoplasms ,Chemotherapy and Drug Treatment ,medicine.disease ,Survival Analysis ,Signaling Cascades ,respiratory tract diseases ,Non-Small Cell Lung Cancer ,Meta-analysis ,Computer Science ,Medicine ,lcsh:Q ,Erlotinib ,business ,Information Technology ,medicine.drug ,Research Article ,Signal Transduction - Abstract
BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. METHODS: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3 or 4 adverse event (AEs). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials. RESULTS: Eight eligible trials involved 2417 patients were ultimately identified. The intention to treatment (ITT) analysis demonstrated that combining targeted therapy significantly improved OS (HR 0.90, 95% CI: 0.82-0.99, p = 0.024), PFS (HR 0.83, 95% CI: 0.72-0.97, p = 0.018), and ORR (OR 1.35, 95% CI 1.01-1.80, P = 0.04). Sub-group analysis based on phases of trials, EGFR-status and KRAS status also showed that there was a tendency to improve PFS and OS in combining targeted therapy, except that PFS for patients with EGFR-mutation or wild type KRAS favored erlotinib monotherapy. Additionally, more incidence of grade 3 or 4 rash, fatigue and hypertension were observed in combining targeted therapy. CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. More studies are still needed to identify patients who will most likely benefit from the appropriate combining targeted therapy.
- Published
- 2013
9. The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data
- Author
-
Hui Zhao, Hongtao Li, Li-Na Tang, Yang Yao, Daliu Min, Zan Shen, Zhiyu Wang, Aina He, Yuanjue Sun, Wei-Xiang Qi, and Shuier Zheng
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Clinical Research Design ,Epidemiology ,MEDLINE ,medicine.medical_treatment ,Orthopedic Surgery ,lcsh:Medicine ,Bone Neoplasms ,Bioinformatics ,Pediatrics ,Disease-Free Survival ,Ezrin ,Internal medicine ,Bone and Soft Tissue Sarcomas ,medicine ,Humans ,lcsh:Science ,Prospective cohort study ,Osteosarcoma ,Chemotherapy ,Multidisciplinary ,business.industry ,lcsh:R ,Hazard ratio ,Cancers and Neoplasms ,Odds ratio ,medicine.disease ,Immunohistochemistry ,Confidence interval ,Neoplasm Proteins ,Gene Expression Regulation, Neoplastic ,Survival Rate ,Cytoskeletal Proteins ,Biomarker Epidemiology ,Surgical Oncology ,Pediatric Oncology ,Meta-analysis ,Medicine ,Female ,Surgery ,lcsh:Q ,Meta-Analyses ,business ,Research Article - Abstract
Background The significance of ezrin immunoexpression and prognosis for osteosarcoma is still controversial. The aim was to provide a meta-analysis for ezrin immunoexpression and prognostic features of osteosarcoma patients. Methods A detailed search was made in MEDLINE, EMBASE and the Web of Knowledge for relevant original articles published in English; methodological quality of the included studies was also assessed. Two reviewers extracted data independently. Studies were pooled and summary hazard ratios (HRs) and odds ratio (ORs) with corresponding confidence intervals (CIs) were calculated. Results Final analysis of 318 patients from 5 eligible studies was performed. Combined HR of ezrin immunohistochemical staining suggested that positive immunoexpression had an unfavorable impact on osteosarcoma patients' overall survival (n = 223 in 4 studies; HR = 4.79; 95% CI: 1.50–15.30; P = 0.008) but not on event-free survival (n = 202 in 3 studies; HR = 1.59; 95% CI: 0.61–4.15; P = 0. 0.342). Combined OR of ezrin immunohistochemical staining indicated that positive immunoexpression was associated with recurrence (n = 134 in 2 studies; OR = 3.79; 95% CI: 1.49–9.64; P = 0.005) but not with serum ALP level (n = 160 in 2 studies; OR = 2.16; 95% CI: 0.09–52.50; P = 0.637) and histological response to neoadjuvant chemotherapy(n = 260 in 4 studies; OR = 0.87; 95% CI: 0.37–2.03; P = 0.740). Conclusions The results of this meta-analysis suggest that ezrin positive immunoexpression confers a higher risk of recurrence and a worse survival in osteosarcoma patients. Large prospective studies are needed to provide solid data to investigate the precise prognostic significance of ezrin.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.